Moderna Inc. and Novocol Pharma announce fill-finish agreement for mRNA vaccines manufactured in Canada
May 04, 2023
On May 4, 2023, Moderna, Inc. ("Moderna") announced its long-term agreement with Novocol Pharma to perform fill-finish labelling and packaging of Canadian-made mRNA vaccines. Fill-finish sterile manufacturing is the last step in the vaccine production cycle that involves transferring the vaccine into vials and packaging. This agreement results in the fill-finish capacity of Moderna vaccines manufactured at its Laval-based mRNA facility, which is anticipated to open at the end of 2024.
Moderna is a pharmaceutical and biotechnology company that focuses on RNA therapeutics, headquartered in Cambridge, Massachusetts.
Novocol Pharma is a leading sterile injectable contract development and manufacturing organization, headquartered in Cambridge, Ontario.
McCarthy Tétrault advised Moderna with a team led by Philippe Leclerc and Véronique Wattiez Larose.